Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Journey Medical Corp (DERM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: DERM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.93% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 218.99M USD | Price to earnings Ratio - | 1Y Target Price 13.5 |
Price to earnings Ratio - | 1Y Target Price 13.5 | ||
Volume (30-day avg) 4 | Beta 0.81 | 52 Weeks Range 3.54 - 9.40 | Updated Date 12/1/2025 |
52 Weeks Range 3.54 - 9.40 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.03 | Actual -0.09 |
Profitability
Profit Margin -14.58% | Operating Margin (TTM) -8.67% |
Management Effectiveness
Return on Assets (TTM) -4.6% | Return on Equity (TTM) -47.05% |
Valuation
Trailing PE - | Forward PE 26.88 | Enterprise Value 219339753 | Price to Sales(TTM) 3.69 |
Enterprise Value 219339753 | Price to Sales(TTM) 3.69 | ||
Enterprise Value to Revenue 3.69 | Enterprise Value to EBITDA 17.72 | Shares Outstanding 21135905 | Shares Floating 14649318 |
Shares Outstanding 21135905 | Shares Floating 14649318 | ||
Percent Insiders 31.39 | Percent Institutions 41.31 |
Upturn AI SWOT
Journey Medical Corp
Company Overview
History and Background
Journey Medical Corp. was founded in 2014. The company focuses on acquiring, commercializing, and marketing pharmaceutical products for dermatological conditions and has grown through strategic acquisitions and product development.
Core Business Areas
- Dermatology Products: Development, marketing, and sale of prescription dermatological products for conditions such as acne, rosacea, and fungal infections.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical sales and marketing. The organizational structure consists of functional departments focused on product development, commercialization, and sales.
Top Products and Market Share
Key Offerings
- Qbrexza: Topical anticholinergic indicated for the treatment of primary axillary hyperhidrosis (excessive sweating). Competitors include topical antiperspirants and Botox injections. Revenue from this product is not readily available.
- Accutane: An oral retinoid indicated for the treatment of severe recalcitrant nodular acne. Competitors include other isotretinoin products and alternative acne treatments. Market share data and revenue from this product are not readily available.
- Exelderm: Exelderm (sulconazole nitrate) is an antifungal cream used to treat fungal infections. Competitors include clotrimazole and miconazole. Market share data and revenue from this product are not readily available.
Market Dynamics
Industry Overview
The dermatology market is driven by the prevalence of skin conditions and increasing demand for effective treatments. The industry is characterized by innovation in topical and systemic therapies.
Positioning
Journey Medical Corp. aims to establish a portfolio of established and emerging dermatological products, often focusing on niche markets or areas where other companies have reduced investment.
Total Addressable Market (TAM)
The global dermatology market is estimated to be in the billions of dollars. Journey Medical Corp. targets specific segments within this TAM, focusing on product acquisitions and commercialization to achieve growth. Actual TAM is difficult to precisely estimate without proprietary data.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Experienced management team
- Focus on niche markets
- Strategic acquisitions
Weaknesses
- High debt levels
- Dependence on key products
- Limited R&D capabilities
- Reliance on third-party manufacturers
Opportunities
- Acquisition of additional products
- Expansion into new markets
- Development of new formulations
- Partnerships with other pharmaceutical companies
Threats
- Generic competition
- Regulatory changes
- Pricing pressures
- Changing consumer preferences
Competitors and Market Share
Key Competitors
- VRX
- AGN
- LLY
- MRK
Competitive Landscape
Journey Medical Corp. is smaller than major pharmaceutical companies but focuses on specific dermatological niches. Competitive advantages include their targeted approach and product portfolio.
Major Acquisitions
Qbrexza
- Year: 2018
- Acquisition Price (USD millions): 150
- Strategic Rationale: Expanded portfolio into hyperhidrosis treatment, providing a novel topical option. (Acquired from Brickell Biotech)
Growth Trajectory and Initiatives
Historical Growth: Growth has been achieved through strategic acquisitions and commercialization of existing products.
Future Projections: Future projections would need analyst estimates that are not available and would be included here.
Recent Initiatives: Recent initiatives include acquiring new products and expanding their sales force.
Summary
Journey Medical Corp focuses on niche dermatology markets. It has experienced growth through acquisitions and sales of specialized products. High debt levels and dependence on key products present challenges. Future success hinges on acquiring new revenue sources to offset generic products.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party Financial Analysis Sites
- News Articles
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Financial data and market share are estimates based on available public information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Journey Medical Corp
Exchange NASDAQ | Headquaters Scottsdale, AZ, United States | ||
IPO Launch date 2021-11-12 | Founder, President, CEO & Director Mr. Claude Maraoui | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 41 | Website https://journeymedicalcorp.com |
Full time employees 41 | Website https://journeymedicalcorp.com | ||
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.